Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hsiehchen

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
American Journal of Clinical Oncology|August 18, 2020
Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell CarcinomaSuleyman Y Goksu, Muhammet Ozer, Syed M A Kazmi, et al.
Cancer Research Communications|July 24, 2023
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular CarcinomaStephanie L Alden, Mir Lim, Chester Kao, et al.
The Oncologist|September 14, 2022
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular CarcinomaJoseph W Franses, Mir Lim, Adam M Burgoyne, et al.
Oncoimmunology|January 10, 2022
Association between immune-related adverse event timing and treatment outcomesDavid Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, et al.
Journal for Immunotherapy of Cancer|August 14, 2023
T-cell tolerant fraction as a predictor of immune-related adverse eventsJared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, et al.
Cancer Medicine|May 22, 2023
Characteristics and clinical outcomes in young-onset cholangiocarcinomaSarah Reddy, Suleyman Yasin Goksu, Nina N Sanford, et al.
Cancers|September 9, 2020
Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine TumorSuleyman Yasin Goksu, Muhammet Ozer, Syed Mohammad Ali Kazmi, et al.
Cancers|October 20, 2020
Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine TumorsSuleyman Yasin Goksu, Muhammet Ozer, Muhammad S Beg, et al.
British Journal of Cancer|June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasmsT R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
Hepatology Communications|April 27, 2023
Multidisciplinary care for patients with HCC: a systematic review and meta-analysisKarim Seif El Dahan, Annika Reczek, Darine Daher, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Oncology|August 18, 2020
Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell CarcinomaSuleyman Y Goksu, Muhammet Ozer, Syed M A Kazmi, et al.
Cancer Research Communications|July 24, 2023
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular CarcinomaStephanie L Alden, Mir Lim, Chester Kao, et al.
The Oncologist|September 14, 2022
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular CarcinomaJoseph W Franses, Mir Lim, Adam M Burgoyne, et al.
Oncoimmunology|January 10, 2022
Association between immune-related adverse event timing and treatment outcomesDavid Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, et al.
Journal for Immunotherapy of Cancer|August 14, 2023
T-cell tolerant fraction as a predictor of immune-related adverse eventsJared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, et al.
Cancer Medicine|May 22, 2023
Characteristics and clinical outcomes in young-onset cholangiocarcinomaSarah Reddy, Suleyman Yasin Goksu, Nina N Sanford, et al.
Cancers|September 9, 2020
Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine TumorSuleyman Yasin Goksu, Muhammet Ozer, Syed Mohammad Ali Kazmi, et al.
Cancers|October 20, 2020
Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine TumorsSuleyman Yasin Goksu, Muhammet Ozer, Muhammad S Beg, et al.
British Journal of Cancer|June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasmsT R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
Hepatology Communications|April 27, 2023
Multidisciplinary care for patients with HCC: a systematic review and meta-analysisKarim Seif El Dahan, Annika Reczek, Darine Daher, et al.
Pageof 7